New drug duo targets genetic flaws in Tough-to-Treat head and neck cancer
Disease control
Completed
This early-phase trial tested the safety and initial effectiveness of a two-drug combination (tipifarnib and alpelisib) for adults with advanced head and neck cancer that had returned or spread. The study focused on patients whose tumors had specific genetic markers (HRAS or PIK3…
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC